Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create best-in-class new drugs in the areas of cancer, infection and autoimmune disease. The company's work has been endorsed by partnerships with global pharmaceutical companies and the NHS.
Redx Pharma's cancer subsidiary, Redx Oncology, has developed novel, differentiated, reversible small molecule inhibitors of Bruton's tyrosine kinase (BTK) and will be presenting its poster to the scientific community next week at the AACR's 2016 annual gathering. Redx's lead compound has a favorable in vitro safety profile and drug-like properties, displaying an improved CYP profile to competitor compounds. In vivo PK demonstrated good oral bioavailability.
This breakthrough is part of Redx's work to develop best-in-class treatments for leukaemia, other blood cancers, and autoimmune diseases such as rheumatoid arthritis, lupus, and Sjögren's Syndrome.
Discovering and developing new therapeutics in the area of infectious disease generating a pipeline of novel antibacterial & antiviral drugs.
Modulating the immune system with novel small molecules to treat a range of diseases with high unmet medical need.
Applying our proprietary method to deliver multiple development candidates across a range of mechanistic approaches in cancer treatment.